PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE MGL-3196 (RESMETIROM) IN PATIENTS WITH MASH WHO HAVE UNDERGONE LIVER TRANSPLANT FOR MASH CIRRHOSIS OR OTHER ETIOLOGIES

Registry ID: MGL-3196-27
Source registry: HEALTH_CANADA
Status: Pending
Phase: PHASE2
Study type: INTERVENTIONAL
Sponsor: MADRIGAL PHARMACEUTICALS INC
Last update: 2026-04-09

Conditions

NONALCOHOLIC STEATOHEPATITIS (NASH)

Related clinical trials

A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III TRIAL EVALUATING LONG-TERM EFFICACY AND SAFETY OF SURVODUTIDE WEEKLY INJECTIONS IN ADULT PARTICIPANTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC ASSOCIATED STEATOHEPATITIS (NASH/MASH) AND (F2) - (F3) STAGE OF LIVER FIBROSIS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH NON-CIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS (SYNCHRONY-HISTOLOGY)
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN ADULTS WITH PRECIRRHOTIC NONALCOHOLIC STEATOHEPATITIS
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFECT OF RESMETIROM ON LIVER-RELATED OUTCOMES IN PATIENTS WITH WELL-COMPENSATED (CHILD-PUGH A) NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS (MAESTRO-NASH OUTCOMES)

View on source registry